|
|
||||||||
Are Expressed on Double-Negative (CD3+CD4-CD8-) and CD8+ T Cells
Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, Twinbrook II Facility, National Institutes of Health, Rockville, MD 20852
| Abstract |
|---|
|
|
|---|
(TCRA) expression was examined in RNA samples from PBMC and
isolated populations of CD4+, CD8+, and DN T
cells from 15 healthy individuals. The expressed TCR repertoire was
surveyed using spectratype analysis, a technique that displays the
distribution of complementarity determining region 3 (CDR3) lengths for
each TCRAV gene family. The results revealed the presence of unusual
populations of double-negative (DN;
CD4-CD8-CD3+) T cells that
express invariant or conserved TCRAV4A, AV7, AV19, and AV24 chains.
Each of the conserved TCRA families was over-represented in >70% of
the individuals studied, and all individuals expressed at least one of
the over-represented TCRAV families. Over-represented conserved AV4A or
AV7 sequences were also present in CD8+ T cells from most
donors. The extent of TCRA sequence conservation is unparalleled.
TCRAV4A, AV19, and AV24 sequences were invariant, although AV4A
and AV19 transcripts contained N region additions. TCRAV24 transcripts
derived from the direct juxtaposition of V and J gene segments. TCRAV7
sequences showed some diversity in two amino acids encoded at junctions
of V and J gene segments. Although derivation of DN T cells with
conserved TCRA chains is puzzling, the wide-spread expression of these
unusual cells suggests an important
function. | Introduction |
|---|
|
|
|---|
- and a
ß-chain. Crystal structures of
ßTCR, MHC, and peptide complexes
have revealed contact between residues in MHC peptide and both the
-
and ß-chains of the TCR (2, 3, 4). The region of the TCR
that is primarily involved in Ag-MHC contact is the complementarity
determining region 3
(CDR3),2 which is the
most variable region of both
- and ß-chains. The TCRß (TCRB)
repertoire of healthy individuals and of individuals with certain
diseases has been investigated (5, 6, 7, 8), whereas the
expressed TCR
(TCRA) repertoire has not been extensively
characterized. The TCRA gene complex spans 1072 kb on chromosome 14.
The TCRA gene complex consists of 42 variable (V) gene segments that
are grouped into 32 families based upon >75% identity at the
nucleotide level (9). The TCRAV gene segments recombine
with 1 of 61 TCRA joining (J) gene segments encoded in a 33-kb region
located 5' of the
constant region (TCRAC) gene segment
(10). Diversity in the TCRA CDR3 derives from different
combinations of V and J gene segments and from N region nucleotides
that are added somatically. In the present report, TCRA expression of healthy individuals was investigated by using spectratype and sequence analyses. Spectratype analysis is a technique that displays the array of CDR3 lengths associated with each TCRAV family (5, 6, 7, 8). Mean distributions of CDR3 lengths for the 32 TCRA families were established by analyses of PBMC, CD4+, CD8+, and DN T cells from 15 healthy adult individuals. Gaussian distributions of CDR3 lengths were observed for CD4+ T cells, and deviations from Gaussian distributions were observed increasingly in PBMC, CD8+, and DN T cells, respectively. Similarities were observed in the size of a skewed peak in AV4A, AV7, AV19, AV24, and AV31 families. Sequence analyses revealed invariant or conserved sequences in AV4A, AV7, AV19, and AV24 that were present in multiple unrelated individuals. In addition, the same AV4A and AV7 sequences were over-represented in the CD8+ T cell subpopulations.
| Materials and Methods |
|---|
|
|
|---|
The complete sequence of the TCRA gene complex has been
entered in GenBank (accession no. AE000521). Sequences of 42 TCRAV
genes were aligned using MAP (multiple sequence alignment program).
TCRAV genes were grouped into 32 subfamilies based on the standard of
75% or greater nucleotide identity. PCR primers were designed to
amplify all members of each VA family, but to contain sufficient
mismatches with other TCRAV families to minimize the possibility of
amplifying other TCRAV genes. The 34 AV primers used for PCR
amplification in these experiments are listed in Fig. 1
.
|
Conserved sequences at the 3' end of TCRAV
(Y-L/F-C-A-
) and at the 5' end of TCRAJ gene segments (F-G-
-G-T)
serve as markers in the definition of the CDR3 region. The
corresponds to any amino acid. The CDR3 region includes amino acids
beginning with the third amino acid after the invariant C residue in
all TCRAV genes (Y-L/F-C-A-
-1) and spans to
the amino acid immediately preceding the TCRAJ motif
(2-F-G-
-G-T).
PBMC isolation and T cell separation
Peripheral blood (50100 ml) was taken from 15 healthy adult individuals by venipuncture, and PBMC were subsequently isolated by centrifugation of the blood over lymphocyte separation medium, a ficoll derivative (Organon Technika, Durham, NC). The PBMC were enumerated and an aliquot of 5 x 106 cells was kept on ice (4°C) as the unfractionated PBMC population. The remaining cells were incubated with anti-CD14- and anti-CD19-coated magnetic beads (Miltenyi Biotec, Sunnyvale, CA) at 4°C for 15 min in a volume of 100 µl/107 cells. After incubation and one wash, the cell-bead mixture was applied to a MACS AS separation column attached to a SuperMACS (Miltenyi Biotec) separation magnet to deplete the population of B lymphocytes and monocytes. The T lymphocyte enriched population was then incubated with anti-CD8 (Leu-2A) MACS MicroBeads (Miltenyi Biotec) and passed through a MACS AS column to collect CD8- cells, and CD8+ T cells were eluted from the magnetic beads according to the manufacturers instructions. The CD8- cell population was then incubated with anti-CD4 (Leu-3A) (Miltenyi Biotec) and passed through a MACS AS column to collect CD4-CD8- (DN) cells, and CD4+ T cells were eluted. The CD8+- and CD4+-enriched and the DN populations were then washed, enumerated, and kept for subsequent analysis. Following the same procedure, certain DN samples were separated into CD56- and CD56+ populations using anti-CD56 (NCAM 16.2) MicroBeads (Miltenyi Biotec).
RNA extraction and cDNA synthesis
Total RNA was prepared from PBMC and T cell subsets using the RNeasy Total RNA Minikit (Qiagen, Santa Clarita, CA). Total RNA (up to 20 µg) was eluted from each column and used as the template for first strand cDNA synthesis. The reaction primer oligo(dT)(12, 13, 14, 15, 16, 17, 18) (2.5 µg) was annealed to the eluted RNA by incubation at 70°C for 10 min. The reaction mixture was brought up to a total volume of 100 µl (50 mM Tris-HCl, 75 mM KCl, 5 mM MgCl2, 10 mM DTT, and 500 mM each dNTP), and cDNA synthesis was completed by primer extension with SuperScript II RNase H- reverse transcriptase (500 U/reaction) (Life Technologies, Gaithersburg, MD) at 42°C for 2 h. The cDNA was diluted 1:5 with DNase-free H2O and stored at -80°C before use as the template for PCR amplification.
TCR spectratype analysis
PCR amplification was performed in a total reaction volume of 50 µl (10 mM Tris-HCl, 50 mM KCl, 1.5 mM MgCl2, and 200 mM each dNTP), using AmpliTaq Gold DNA polymerase (1 U/reaction) (PE-Applied Biosystems, Foster City, CA). Reactions were primed with the TCRAC region-specific oligonucleotide oTCA4 and each of the TCRAV region specific oligonucleotides (1 mM final concentration) and submitted to 35 cycles of amplification. Reaction conditions consisted of an initial incubation at 95°C for 12 min (to activate Amplitaq Gold), followed by template denaturation at 95°C for 30 s, primer annealing at 60°C for 30 s, and primer extension at 72°C for 90 s. Five microliters of each PCR product was then used as template for a single-stranded primer-extension reaction using the same reaction mix as for PCR amplification in a total volume of 20 µl. This reaction was primed with a nested TCRAC region fluorescently labeled oligonucleotide oTCRAC (6-FAM fluorophore; Life Technologies). Primer extension was performed using AmpliTaq DNA polymerase (0.5 U/reaction) (PE-Applied Biosystems) and 3 cycles of template denaturation at 95°C for 2 min, primer-annealing at 60°C for 2 min, and primer-extension at 72°C for 10 min. Fluorescent products were analyzed by separation on a 4% acrylamide, 6 M urea sequencing gel using an ABI-377 DNA sequencer (PE-Applied Biosystems). The gel-loading mix consisted of 2 µl of primer-extension reaction product, 2 µl of formamide, 0.5 µl of loading dye (25 mM EDTA, 50 mg/ml blue dextran), and 0.5 µl of GeneScan-500 TAMRA dye-labeled size standards (PE-Applied Biosystems). This mixture was denatured at 95°C for 2 min, and 2 µl was loaded onto the gel and run for 2 h. DNA products of the appropriate lengths were analyzed using GeneScan software version 2.1 (PE-Applied Biosystems), and areas under each peak were used for subsequent analysis.
Flow cytometric analysis
PBMC from healthy individuals were isolated by ficoll
density gradient centrifugation and washed three times in PBS. Cell
purity after magnetic bead separation was determined by staining with
FITC-conjugated anti-CD4 or CD8, PE-conjugated anti-CD3 or
CD56, and PerCP conjugated anti-CD8, CD4, or CD56 (Becton
Dickinson, Mountain View, CA) for 30 min on ice. Stained cells were
washed twice in PBS containing 1% FCS and 0.01% sodium azide before
analysis on a Becton Dickinson FACScan. Lymphocytes were gated on
forward versus side scatter, and 10,000 events were collected. Analysis
was performed using the CellQuest software, and markers were based on
unstained controls. Other Abs used for staining, but for which data are
not shown, include anti-VA24 (Immunotech, Westbrook, ME) and
FITC-conjugated anti-TCR
ß, TCR
, CD16, CD44, and goat
anti-mouse Ig (Becton Dickinson).
Quantitative analysis
A formal mathematical analysis of the data was performed
to permit an objective and sensitive determination of the magnitude of
perturbation or skewing of a given CDR3 profile from a Gaussian
distribution. After analysis using GeneScan software, data from each
CDR3 profile were imported into a spreadsheet and translated into a
probability distribution, P (i) =
Ai/(
iAi)
(11). The area under the curve (Ai)
of each CDR3 peak (i), corresponding to a discrete amino acid length,
was expressed as fraction of the total area under the profile
(
iAi). To provide a
baseline for the calculation of generalized hamming distances (HD) for
each profile, the average probability distribution was calculated for
each AVj family using the
CD4+ profiles obtained from 15 individuals,
Pj (i) =
j[Pj(i)]/15. This was
performed for each AV family, since some families consistently showed a
larger number of possible CDR3 lengths than others (ranges from 7 to
11), and some families have different mean CDR3 lengths. A normal
distribution was then fit to the average distribution profiles and used
to represent the theoretical unperturbed repertoire for each
AVj family. The generalized HD was then used to
calculate the degree of skewing or perturbation of any given profile
from the predicted normal distribution. The extent of perturbation or
skewing at each TCR length, Di =
Pi (observed) - Pi
(expected) was calculated for each profile. The HD for each profile was
then calculated using the formula: HD =
100[
i D (i)]/2, where
[
i D (i)] is the sum of the absolute
differences of the distances between two probability distributions at
each TCR length. For a profile showing no perturbation from normal, the
value for HD = 0%, while two completely discordant profiles will
have an HD = 100%, and two randomly drawn profiles should have an
HD = 50%. The HD-scoring method was used, as it is a more robust
test for biological significance than the
2 test.
TCRA sequencing
DNA sequence analyses were performed on selected samples by ligation of 0.51 ng of PCR product with pCR2.1 vector (TA cloning kit; Invitrogen, Carlsbad, CA) at 16°C overnight. OneShot competent cells (Invitrogen) were used for the transformation. After PCR screening, positive colonies were selected and expanded. Plasmids were purified, inserts were sequenced using an ABI 377 DNA sequencer, and the sequence data were analyzed using Factura software.
| Results |
|---|
|
|
|---|
The extent of diversity in the human TCRA repertoire was
examined by spectratype analysis, a technique that provides a
quantitative assessment of the array of CDR3 lengths present in
transcribed TCRA chains. It was possible to design primers that detect
the members of all 32 functional TCRAV families (Fig. 1
) from the
sequence of the complete TCRA gene complex available in GenBank. For
both AV1 and AV4 families, two primers were necessary because of
sequence variation among subfamily members.
A complete TCRA spectratype analysis of the PBMC from a healthy adult
individual is shown in Fig. 2
. Profiles
of the 32 TCRAV families show distributions of CDR3 lengths that differ
by 3 bp and correspond to in-frame TCRA transcripts. The length of the
CDR3 region can be deduced from the lengths of the PCR products when
compared with that derived from a TCRA chain clone with a known
sequence. In this experiment, TCRA CDR3 lengths ranged from 3 aa to 19
aa. For most of the TCRAV families, the distribution of CDR3 lengths
appeared as a Gaussian distribution by visual examination. However,
there were certain notable exceptions. The TCRAV profiles for the
individual shown in Fig. 2
showed single dominant peaks in the
spectratype profiles of AV4A, AV7, AV29, and AV30 and skewed profiles
for AV3, AV8, AV12, AV24, AV26, AV27, and AV31. Skewed TCRB spectratype
profiles have been observed in peripheral CD8+ T
cells of healthy individuals and have been shown to represent clonal or
oligoclonal expansions of the TCRBV family within the
CD8+ T cell subset (12, 13, 14, 15, 16). It was
next asked whether skewed distribution of CDR3 lengths within TCRAV
families reflected a clonal or oligoclonal expansion within a single T
cell subset.
|
PBMC were depleted of B cells and monocytes using a combination of anti-CD14- and anti-CD19-coated magnetic beads. CD8+ and CD4+ T cells were isolated sequentially by positive selection using anti-CD8- then anti-CD4-coated magnetic beads. The remaining cells comprised the CD4-8- or DN population. The isolated cell populations were tested for purity by flow cytometry using anti-CD3, anti-CD4, and anti-CD8; the average purity was 97% for the CD4+, 86% for the CD8+, and 94% for the DN populations.
Spectratype analysis was performed on PBMC, and isolated populations of
CD4+, CD8+, and DN T cells from 15 unrelated
healthy adult individuals. A total of 2040 spectratype profiles were
produced, and each was compared with a normal distribution. A formal
quantitative assessment designated HD was applied to give a numerical
value for the degree to which a profile deviates from an idealized
normal distribution. For example, a profile with an HD score of 0%
shows total concordance with a normal distribution, whereas a profile
with an HD score of 100% shows complete discordance. The HD scores for
each TCRAV family in the 15 individuals are shown by a dot in Fig. 3
with representative profiles for the
ranges of HD scores shown at the top of the figure.
|
|
Similarities in spectratype profiles of DN T cells among multiple individuals
Examination of the mean profiles for each TCRAV family,
combining data from all 15 individuals studied, revealed similarities
in spectratype profiles of DN T cells. Skewing in the mean profile
would reflect that the same CDR3 length was over-represented in
multiple individuals. The mean spectratype profiles of five TCRAV
families showed non-Gaussian distributions in DN populations with one
CDR3 length represented at frequencies between 1.8 and 4.3 times
greater than expected for a normal distribution (Fig. 4
).
|
|
|
Similarities in spectratype profiles of CD8+ cells among multiple individuals
Fig. 5
also reveals skewed
profiles for TCRAV4A and AV7 in the CD8+
subpopulation for the individuals shown. The size of the peak in the
CD8+ T cells is identical to that present in the
DN subpopulation. The mean CD8+ spectratype
profiles for TCRAV4A and AV7 families were examined to determine
whether skewed profiles were observed in multiple individuals. The mean
profiles of AV4A and AV7 families for CD8+ cells
showed non-Gaussian distributions of CDR3 lengths. TCRAV4A
transcripts with a CDR3 length of 9 aa were present 2.4 times more
frequently than expected and were over-represented in 10 of the 13
individuals, who also showed this length over-represented in their DN
cells. TCRAV7 transcripts corresponding to a CDR3 of 8 aa were
over-represented (3.5 times) in all of 14 individuals with that length
CDR3 over-represented in their DN population (Table II
). The TCRAV4A
and AV7 peaks were also evident in the PBMC (Fig. 5
). One individual
showed over-representation of same-sized AV24 peak in both DN and
CD8+ cells (11 aa), and one individual showed
over-representation of same sized AV19 peak in both DN and
CD8+ cells (9 aa). Skewing observed in the
remaining TCRAV families was variable among individuals in CDR3 length
and occurrence.
Stability of TCRA spectratype profiles over time
Full TCRA spectratype profiles were determined on seven individuals on at least two different occasions with blood samples taken 3 mo to 2 yr apart. The patterns of expression of the four conserved TCRAV families were consistent over time. Over-representation of TCRAV4A, AV7, AV19, and AV24 was consistently maintained within the same T cell subsets in all individuals. Individuals who were negative for the over-representation of a TCRAV family remained negative. Two individuals with TCRAV4A over-represented in DN but not CD8+ T cells maintained that pattern over a 2-yr period. Thus, the expression of conserved TCRAV4A, AV7, AV19, and AV24 families is stable in healthy adult individuals.
Sequence analysis of TCRA transcripts with over-represented CDR3 lengths
Spectratype analysis identifies CDR3 lengths within a TCRA family
that are over-represented, but does not reveal the extent of diversity
in the transcripts having that CDR3 length. Analyses were performed to
determine the sequences of transcripts in the five TCRAV families that
showed an over-represented CDR3 length. Samples from four to eight
individuals with the over-represented CDR3 length in the DN populations
and samples from one to seven individuals with the over-represented
CDR3 length in CD8+ cells were cloned and
sequences were determined. Absolutely conserved or predominant
sequences were observed for AV4A, AV7, AV19, and AV24 (Fig. 6
), whereas AV31 sequences were unique to
each individual.
|
The presence of conserved TCRAV7 in the DN T cells has been reported
(17), but their presence in the CD8+
population was not noted in this study. A total of 177 TCRAV7 clones
from DN and CD8+ T cell populations derived from
7 donors were sequenced, and 139 clones had a CDR3 of 8 aa. Of the
clones with an 8-aa CDR3 length, 123 clones utilized TCRAJ33. Diversity
was observed in the two amino acids encoded at the junction of V and J
gene segments (marked by a
in Fig. 6
). A valine residue was the
most frequently observed amino acid in the first variable position
(92/123), which, according to the numbering system used here, would be
considered part of the V gene segment. Methionine was the most
frequently observed residue in the second variable amino acid position
(54/123); Val and Met were present together in 38/123 clones. There
were 16 clones with an 8-aa CDR3 that utilized TCRAJ gene segments
other than the conserved TCRAJ33. A Val residue was present in the
first variable position in all 16 clones, and 4 clones had both Val and
Met residues at corresponding positions in the CDR3. Each individual
expressed numerous different sequences in DN and in
CD8+ cells; many sequences were present in both
cell populations from a single individual.
A total of 30 of 57 clones derived from the DN cell populations of 8 individuals had an invariant TCRAV19 sequence with a CDR3 of 9 aa using AJ48. In addition, one of these individuals showed over-representation of transcripts corresponding to a CDR3 of 9 aa in the CD8+ population, and 8/22 clones from the CD8+ cells of this individual had the invariant TCRAV19 sequence.
The reported invariant TCRAV24 sequence using AJ 18 with a CDR3 of 11 aa (17, 18) was observed in 18 of 35 clones analyzed derived from DN T cells from 4 individuals. In addition, one of these individuals also showed over-representation of transcripts corresponding to a CDR3 length of 11 aa in the CD8+ cell population. Ten clones derived from CD8+ cells were sequenced; none showed the invariant sequence.
Sequences were determined for 54 TCRAV31 clones with a 9-aa CDR3 length derived from six individuals. Comparison of sequences of clones from a single individual showed that all clones were identical. Comparisons of sequences between individuals revealed no sequence similarities. Thus, TCRAV31 transcripts were conserved in CDR3 length, but not in sequence.
Origin of conserved TCRA chains
Transcripts from AV4A, AV7, AV19, and AV24 families had
conserved TCRAJ genes and CDR3 sequences. Examination of the origin of
the conserved sequences by comparison of the transcripts with germline
sequences may reveal features that favor these specific rearrangement
events. With availability of the sequence of the full TCRA complex, it
was possible to determine the origin of nucleotides that encode the
CDR3 region. Alignments of cDNA and genomic sequences are shown in Fig. 7
.
|
TCRAV4A transcripts have a CDR3 region of 9 aa with the sequence R-D-V-G-N-T-P-L-V. The R-D residues are encoded by the AV4A gene segment and the G-N-T-P-L-V residues by the TCRAJ29 gene segment. The central valine residue is the result of N region additions; however, the last nucleotide of the codon may derive from AJ29. The invariant TCRAV19 sequence had a 9-aa CDR3 with the sequence K-N-F-G-N-E-K-L-T. Most of the CDR3 is encoded by the TCRAJ48 gene segment with the leading lysine residue encoded by N nucleotides. It is possible for the first residue of the lysine codon to derive from the AV19 gene segment. Genomic sequences of the TCRAV4A and TCRAV19 gene segments were confirmed in five of the donors in this study.
In contrast, limited diversity is present in TCRAV7 clones using the TCRAJ33 gene segment with a CDR3 of 8 aa. There are two TCRAV7 genes; however, most of the conserved AV7 clones (118/122) utilized the AV7.2 gene segment rather than the AV7.1 gene segment. Diversity in the conserved TCRAV7 transcripts is found in the two residues that border the junction of V and J gene segments. According to the definition of the CDR3 used here, the first variable residue lies in the V region. The germline sequences in part account for the predominance of valine and methionine residues in the variable positions. Codons for valine and methionine residues are present in the AV7 and AJ33 gene segments, respectively. Some diversity arose from variation in the direct joining of V to J gene segments, and additional diversity arose from N region nucleotides. For example, there is 4-fold redundancy in valine codons, and all four codons were found in the clones.
The distribution of conserved TCRAV into CD56+ and CD56- DN T cells
The invariant TCRAV24 has been reported to be present on DN T
cells that express NK markers (19, 20, 21). The representation
of the other conserved TCRAV families in DN NK+
and NK- populations was investigated. Isolated
DN cell populations were separated into NK+ and
NK- populations using anti-CD56 magnetic
beads, and the resulting NK- populations
(CD56-depleted) were >98% pure. Spectratype profiles for AV4A, AV7,
AV19, and AV24 are shown in Fig. 8
. Three
of the four individuals studied, donors 2, 5, and 8, expressed all four
of the over-represented TCRAV families, whereas donor 6 expressed all
but the conserved TCRAV19 sequence.
|
| Discussion |
|---|
|
|
|---|
The T cells with conserved TCRA are puzzling in several ways. First, identical conserved TCRA sequences are found in multiple unrelated individuals, but none of the conserved sequences were detected in all individuals studied. Second, conserved TCRA chains are found on populations of T cells that lack both CD4 and CD8 coreceptor molecules, and, in some individuals, the same conserved TCRA sequences are also found on CD8+ cells. Third, the level of TCRA sequence conservation is extensive in spite of N region additions. Fourth, TCRA chains undergo rearrangement only after a functional TCRB chain has been expressed, yet analyses of TCRB expression have not identified parallel conserved TCRB chains.
Expression of conserved TCRAV sequences in 15 unrelated healthy individuals
The conserved TCRA sequences were found in multiple unrelated individuals from diverse ethnic backgrounds. None of the conserved sequences were observed to be present in all of the individuals studied, although all individuals showed over-representation of at least one of the conserved TCRAV families. Expression of conserved TCRA sequences was stable over time. The same conserved sequences were present, and no additional sequences were detected in an individual at intervals of up to 2 yr. These observations suggest that T cells with conserved TCRA recognize a common Ag that is presented by molecules with limited polymorphism. These data further suggest that the common Ag is persistently present in multiple individuals in the population.
Several studies report that DN T cells with uncharacterized TCR recognize a variety of nonprotein lipid or glycolipid Ags when presented by CD1 molecules (22, 23, 24, 25, 26, 27, 28). Populations of DN T cells with the conserved TCRAV24 have been well characterized in terms of the glycolipid recognized, the cytokines produced in response to Ag, and the participation of costimulatory molecules (17, 18, 19, 20, 21, 29, 30, 31). CD1d has been established to be the Ag-presenting molecule for the invariant TCRAV24-expressing DN T cells.
Expression of conserved TCRAV sequences in T cell subsets
The conserved TCRAV4A, AV7, and AV19 sequences differ from the invariant TCRAV24 in T cell subset localization. TCRAV24 is found on DN and CD4+, but never on CD8+ T cell (19, 20). TCRAV4A and AV7 sequences are present in DN and often in CD8+ T cells. The conserved TCRAV19 sequence was found in the CD8+ population of one of the individuals with it highly represented in their DN population.
A recent study reports that CD8+ T cells can also recognize nonprotein lipids from Mycobacterium tuberculosis in the context of CD1a or CD1c (32). Thus, it is possible that T cells bearing the conserved TCRAV4A, AV7, and AV19 may recognize a nonprotein, lipid, or glycolipid Ag in the context of a highly conserved nonconventional class I-like molecule.
The presence of conserved TCRAV4A and AV7 sequences in CD8+ and DN T cells suggests that these peripheral DN T cells with conserved TCRA chains derive from differentiated CD8+ T cells. Furthermore, CD8+ T cells have been reported to convert to a DN phenotype upon stimulation by specific Ag (33) or a combination of cytokines, PMA, and ionomycin (34). Modulation of coreceptor molecules may not be limited to CD8. The conserved TCRA sequences were found in both CD56+ and CD56- DN subsets, which may be because of CD56 modulation.
Junctional diversity in conserved TCRAV sequences
TCRAV4A, AV7, and AV19 are also distinguished from TCRAV24 by the presence of N region nucleotide additions. TCRAV24 can be the result of a direct joining of TCRAV and TCRAJ gene segments. TCRAV4A and AV19 sequences include N region residues, and, even with the addition of nongermline encoded residues, cDNA sequences from all individuals were identical. Conservation of amino acid sequence suggests selection based upon specificity, but conservation at the mRNA level is puzzling. The possibility that genomic organization would favor certain specific rearrangement events was investigated by examination of the relative positions of the gene segments involved in the conserved sequences within the TCRA gene complex.
The pairs of V and J gene segments found together are not in proximity
to one another in the genome, as shown schematically in Fig. 9
. TCRAV7S1 and AV7S2 are located at the
5' end of the cluster of V gene segments in the TCRAV gene complex,
whereas TCRAV19 is located at the 3' end. The TCRAJ gene segments used
by the conserved transcripts are dispersed across the AJ region and
numbered consecutively 3' to 5' (10). All rearrangement
events involve elements that span considerable distance in the TCRA
gene complex. In addition, the heptamer and nonomer recombination
signal sequences for the paired AV and AJ gene segments were examined.
No striking similarities were evident to suggest preferential joining
among recombination signal sequences.
|
TCRBV expression with conserved TCRAV
Expression of TCRB has been studied in considerably greater depth
than TCRA expression, and conserved sequences in peripheral blood
samples from multiple individuals have not been observed. TCRB
spectratype profiles of PBMC, and isolated populations of
CD4+, CD8+, and DN T cells
were examined in parallel with the present studies. No over-represented
TCRB chains that corresponded to the over-represented TCRA were
observed. Studies of TCRAV24 using a mAb have identified several TCRBV
families associated with the conserved
-chain. Even though certain
TCRBV families seem to be associated with the invariant TCRAV24, there
is significant diversity in CDR3 lengths and sequences (17, 19, 20). It is also possible that several TCRBV families are
used to form the receptor with conserved TCRAV4A, AV7, and AV19 chains.
However, any heterogeneity in the TCRB chain paired with a conserved
TCRA chain presents an enigma because the TCRB chain undergoes
rearrangement before the TCRA chain during development in the
thymus.
Origin of peripheral DN T cells
DN T cells represent the earliest stage of differentiation
in the thymus. In the mature thymus, DN T cells comprise
5% of
total thymocytes and represent at least three discrete populations. One
population expresses TCR 
, another population expresses
TCR
ß, and the remainder are committed to the
ß lineage but
have yet to rearrange their TCR. Upon expression of a functional TCRB
chain, along with the pre-T cell
-chain, both CD4 and CD8 coreceptor
molecules are also expressed on the cell surface (43). The
presence of CD4 and CD8 is critical to the positive and negative
selective forces that shape the peripheral TCR repertoire.
In the periphery, DN T cells (CD3+
CD4-8-) are principally
TCR
-positive, and those with TCR
ß represent only 0.12% of
the PBMC in healthy individuals. The populations of peripheral DN T
cells with conserved TCRA chains may derive from the population of
thymic DN T cells; they may derive from CD4+ or
CD8+ T cells that have modulated the expression
of coreceptor molecules; or, alternatively, they may develop in a
thymus-independent manner. Preliminary spectratype results from human
thymic tissue did not reveal the over-representation of conserved
TCRAV4A, AV7, AV19, and AV24 sequences (unpublished observations).
Therefore, if the conserved DN T cells are derived from DN T cells in
the thymus, skewing of the conserved populations occurs after these
cells have left the thymus, presumably because of stimulation and
expansion by Ag.
The widespread presence of DN T cells with conserved TCRA chains in the population indicates that these cells represent effectors of important immune responses. Furthermore, these data suggest that the Ag-presenting molecules must be highly conserved in the human population. DN T cells with conserved TCRA are unusual cells in terms of the expression of TCR and coreceptor molecules. The extent of conservation of TCRA sequences is unparalleled, and the mechanisms used in the generation of diversity may be unconventional. DN T cells have been recently described to recognize nonprotein lipids or glycolipid Ags (22, 23, 24, 25, 26, 27, 28, 29, 30, 31), but the functions of DN T cells with conserved TCRAV4A, AV7, and AV19 remain to be determined.
| Acknowledgments |
|---|
| Footnotes |
|---|
2 Abbreviations used in this paper: CDR3, complementarity determining region 3; DN, double-negative T cells; TCRB, TCR ß; TCRA, TCR
; TCRAV, TCRA variable region; HD, Hamming distance; aa, amino acid. ![]()
Received for publication March 19, 1999. Accepted for publication April 22, 1999.
| References |
|---|
|
|
|---|
region variable genes. Genomics 38:442.[Medline]
/C
) region: organization, sequence, and evolution of 97.6 kb of DNA. Genomics 19:478.[Medline]
/ß T cells demonstrates preferential use of several Vß genes and an invariant TCR
chain. J. Exp. Med. 178:1.
24-J
Q/Vß11 T cell receptor is expressed in all individuals by clonally expanded CD4-8- T cells. J. Exp. Med. 180:1171.
24+ CD4-CD8- T cells. J. Exp. Med. 186:109.
ß T cells expressing invariant TCR
-chains. J. Immunol. 158:5603.[Abstract]
24 and Vß11 coexpression defines a human NK1 T cell analog containing a unique Th0 subpopulation. J. Immunol. 159:5862.[Abstract]
ß+ T cells. Nature 372:691.[Medline]
24J
Q T cell receptor
chains. J. Exp. Med. 188:867.
ß T cell pool. J. Immunol. 162:366.This article has been cited by other articles:
![]() |
A. Peterfalvi, E. Gomori, T. Magyarlaki, J. Pal, M. Banati, A. Javorhazy, J. Szekeres-Bartho, L. Szereday, and Z. Illes Invariant V{alpha}7.2-J{alpha}33 TCR is expressed in human kidney and brain tumors indicating infiltration by mucosal-associated invariant T (MAIT) cells Int. Immunol., December 1, 2008; 20(12): 1517 - 1525. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. N. Naumov, E. N. Naumova, M. B. Yassai, K. Kota, R. M. Welsh, and L. K. Selin Multiple Glycines in TCR {alpha}-Chains Determine Clonally Diverse Nature of Human T Cell Memory to Influenza A Virus J. Immunol., November 15, 2008; 181(10): 7407 - 7419. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. Wettstein, M. Strausbauch, and N. Borson Repertoires of T cell receptors expressed by graft-infiltrating T cells evolve during long-term recall responses to single minor histocompatibility antigens Int. Immunol., April 1, 2007; 19(4): 523 - 534. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Brigl, P. van den Elzen, X. Chen, J. H. Meyers, D. Wu, C.-H. Wong, F. Reddington, P. A. Illarianov, G. S. Besra, M. B. Brenner, et al. Conserved and Heterogeneous Lipid Antigen Specificities of CD1d-Restricted NKT Cell Receptors J. Immunol., March 15, 2006; 176(6): 3625 - 3634. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Collette, S. Bagot, M. E. Ferrandiz, P.-A. Cazenave, A. Six, and S. Pied A Profound Alteration of Blood TCRB Repertoire Allows Prediction of Cerebral Malaria J. Immunol., October 1, 2004; 173(7): 4568 - 4575. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Illes, M. Shimamura, J. Newcombe, N. Oka, and T. Yamamura Accumulation of V{alpha}7.2-J{alpha}33 invariant T cells in human autoimmune inflammatory lesions in the nervous system Int. Immunol., February 1, 2004; 16(2): 223 - 230. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mantovani, B. Palermo, S. Garbelli, R. Campanelli, G. Robustelli della Cuna, R. Gennari, F. Benvenuto, E. Lantelme, and C. Giachino Dominant TCR-{alpha} Requirements for a Self Antigen Recognition in Humans J. Immunol., December 1, 2002; 169(11): 6253 - 6260. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. D. Gadola, N. Dulphy, M. Salio, and V. Cerundolo V{alpha}24-J{alpha}Q-Independent, CD1d-Restricted Recognition of {alpha}-Galactosylceramide by Human CD4+ and CD8{alpha}{beta}+ T Lymphocytes J. Immunol., June 1, 2002; 168(11): 5514 - 5520. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. P. Chapoval, K. Iijima, E. V. Marietta, M. K. Smart, A. I. Chapoval, A. G. Andrews, and C. S. David Allergic Inflammatory Response to Short Ragweed Allergenic Extract in HLA-DQ Transgenic Mice Lacking CD4 Gene J. Immunol., January 15, 2002; 168(2): 890 - 899. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Mempel, B. Flageul, F. Suarez, C. Ronet, L. Dubertret, P. Kourilsky, G. Gachelin, and P. Musette Comparison of the T Cell Patterns in Leprous and Cutaneous Sarcoid Granulomas : Presence of V{alpha}24-Invariant Natural Killer T Cells in T-Cell-Reactive Leprosy Together with a Highly Biased T Cell Receptor V{alpha} Repertoire Am. J. Pathol., August 1, 2000; 157(2): 509 - 523. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Shinkai and R. M. Locksley CD1, Tuberculosis, and the Evolution of Major Histocompatibility Complex Molecules J. Exp. Med., March 13, 2000; 191(6): 907 - 914. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |